Doctors and detailers: therapeutic education or pharmaceutical promotion?
- PMID: 2583883
- DOI: 10.2190/HUFK-5Y54-QX1E-AD62
Doctors and detailers: therapeutic education or pharmaceutical promotion?
Abstract
Pharmaceutical companies in industrialized countries generally view detailers as the most crucial element in the promotion of their products, with the result that over 50 percent of expenditures on promotion are devoted to detailers. Publicly the companies make claims for the scientific knowledge of detailers and for their role in passing on information to physicians, but the main purpose of detailers is to sell their company's products. This emphasis on sales is evident from statements of detailers themselves, from advertisements for detailers, from company documents, and by looking at the groups of physicians that companies specially target for visits by detailers. A variety of explanations are offered as to why physicians see detailers, but on examination none of the reasons is justifiable. Studies from a number of industrialized countries have shown that over 90 percent of physicians see detailers and a substantial percentage rely heavily on detailers as sources of information about therapeutics. Detailers are highly successful in altering physicians' prescribing habits, but almost all the literature available shows that the more reliant doctors are on commercial sources of information, the less appropriate they are as prescribers. Widespread use of DES (diethylstilbestrol) and the Dalkon Shield was encouraged by detailers. Although detailers have received the endorsement of both physicians' groups and government bodies, seeing detailers is detrimental to the practice of good medicine, and the best interests of doctors and their patients would be served if physicians had nothing further to do with detailers.
Similar articles
-
Interactions between physicians and the pharmaceutical industry: what does the literature say?CMAJ. 1993 Nov 15;149(10):1401-7. CMAJ. 1993. PMID: 8221424 Free PMC article. Review.
-
Pharmaceutical promotion in Canada: convince them or confuse them.Int J Health Serv. 1987;17(1):77-89. doi: 10.2190/4W1H-E70T-TL9X-VGGC. Int J Health Serv. 1987. PMID: 3557776
-
The influences of drug companies' advertising programs on physicians.Int J Health Serv. 2000;30(3):585-95. doi: 10.2190/GYW9-XUMQ-M3K2-T31C. Int J Health Serv. 2000. PMID: 11109183
-
[Dangerous liaisons--physicians and pharmaceutical sales representatives].Acta Med Port. 2005 Jan-Feb;18(1):61-8. Epub 2005 Mar 11. Acta Med Port. 2005. PMID: 16202335 Review. Portuguese.
-
Influence of pharmaceutical promotion on prescribers in Jordan.Int J Clin Pharm. 2020 Apr;42(2):744-755. doi: 10.1007/s11096-020-01006-3. Epub 2020 Mar 5. Int J Clin Pharm. 2020. PMID: 32140917
Cited by
-
Characteristics of materials distributed by drug companies. An evaluation of appropriateness.J Gen Intern Med. 1996 Oct;11(10):575-83. doi: 10.1007/BF02599024. J Gen Intern Med. 1996. PMID: 8945688 Review.
-
Reasons for not seeing drug representatives.BMJ. 1999 Jul 10;319(7202):69-70. doi: 10.1136/bmj.319.7202.69. BMJ. 1999. PMID: 10398608 Free PMC article. No abstract available.
-
Views and Perceptions of Medical Representatives and Physicians about the Role of Medical Representatives and Pharmaceutical Advertisement in Saudi Arabia - A Pilot Study.J Res Pharm Pract. 2023 Aug 29;11(4):127-135. doi: 10.4103/jrpp.jrpp_65_22. eCollection 2022 Oct-Dec. J Res Pharm Pract. 2023. PMID: 37969614 Free PMC article.
-
A survey of pharmaceutical company representative interactions with doctors in Libya.Libyan J Med. 2012;7. doi: 10.3402/ljm.v7i0.18556. Epub 2012 Sep 18. Libyan J Med. 2012. PMID: 23002397 Free PMC article.
-
Interactions between a general practitioner and representatives of drug companies.BMJ. 1993 Jun 19;306(6893):1649. doi: 10.1136/bmj.306.6893.1649. BMJ. 1993. PMID: 8324433 Free PMC article. No abstract available.
MeSH terms
LinkOut - more resources
Full Text Sources
Miscellaneous